1521 (1521) Fair Value & Analysis

Healthcare · Market cap HK$1.9B

1 1521 1521 · HK

PriceHK$0.9500

Fair ValueHK$0.5500

Upside-42.1%

Quality54/100

Evidence: High Range HK$0.4700 – HK$0.7100

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price +35.7% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.7000 – HK$1.77 · fair‑value band HK$0.4700 – HK$0.7100 · the HK$0.9500 price screens above the HK$0.5500 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1521 (1521) currently trades at HK$0.9500, while our model-based Fair Value estimate is HK$0.5500 — implying the stock looks roughly 42.1% overvalued today. We read business quality at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 1521 generated revenue of HK$257M at a net margin of 2.7%. Revenue grew 2.9% year over year. It earns a return on equity of 2.0%. Net debt stands at HK$90.6M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$257M

Revenue growth (YoY) +2.9%

Net margin 2.7%

Return on equity 2.0%

Free cash flow HK$32.3M FY2025

P/E ratio 32.0

More key figures

Operating margin 6.8%

EPS growth (YoY) +324%

Net debt HK$90.6M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1521 reported revenue of HK$257M in FY2025 versus HK$184M in FY2021, a compound +8.6%/yr. Reported net income was HK$6.8M in FY2025, compounding −22.1%/yr from FY2021.

Revenue +8.6%/yr

FY21 HK$184M

FY22 HK$250M

FY23 HK$260M

FY24 HK$255M

FY25 HK$257M

Net income −22.1%/yr

FY21 HK$18.4M

FY22 HK$25.7M

FY23 HK$10.8M

FY24 HK$791K

FY25 HK$6.8M

Is 1521 fairly valued? → Check now

Similar stocks

6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	7,746 MXN	449.62 MXN	-94%
Regeneron Pharmaceuticals, Inc REGN	$635.45	$547.01	-14%
UCB SA UCB	€274.90	€211.40	-23%
argenx SE ARGNF	$900.00	$382.64	-57%
Alnylam Pharmaceuticals, Inc ALNY	$291.22	$111.44	-62%
Samsung Biologics Co 207940	1,000,000 KRW	1,091,384 KRW	+9%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1521 (1521) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.5500 versus a price of HK$0.9500 — about −42% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1521?

Our model-based fair value for 1521 is HK$0.5500 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.9500.

What is the quality score of 1521?

1521 has a Quality Score of 54/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1521 (1521)?

1521 reported trailing-twelve-month revenue of about HK$257M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1521?

The net profit margin of 1521 is about 2.7%, meaning it keeps roughly 2.7% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.